Tag: Multiple Sclerosis
FDA Approves Mavenclad for Treating Multiple Sclerosis
Treatment indicated for patients with relapsing-remitting, active secondary progressive MS
FDA Approves Mayzent for Relapsing Multiple Sclerosis
Oral medication must be dispensed with important information about the drug's uses and risks
Older Age at Puberty Linked to Lower Odds of Multiple Sclerosis
After adjustment for effects on adult BMI, correlation between age at puberty with MS was attenuated
Neighborhood-Level Socioeconomics Tied to MS Disability Progression
Lower socioeconomic status associated with higher risk for multiple sclerosis disability progression
Noncontrast Brain MRI Effective for Monitoring Multiple Sclerosis
Contrast-enhanced sequences do not reveal disease progression missed with nonenhanced sequences
AAN: No Increased MS Relapse Risk in Postpartum Period
Annual relapse rate 0.39 before pregnancy, dropped during pregnancy, rebounded by four to six months
AAN: Sweetened Drinks Linked to More Severe Disability in MS
Those in highest quartile of sugar-sweetened beverage intake had greater risk for severe disability
Cocoa Beverage Could Improve Multiple Sclerosis-Related Fatigue
Small effect seen for fatigue, moderate effect on fatigability as measured by six-minute walk test
Contributors to Delay of Multiple Sclerosis Diagnosis ID’d
First symptoms, MS type contribute to delay; depression linked to delay in evaluation-to-diagnosis time
Early Intensive Treatment May Improve Long-Term MS Outcomes
Mean five-year change lower in Expanded Disability Status Scale score with early intensive treatment
